Kromek Group plc (LSE:KMK), the County Durham-based radiation and bio-threat detection company, is drawing attention on London's AIM market as it heads towards its Annual General Meeting on 23 October 2026. The company published its Annual Report and notice of meeting on 2 October, alongside board changes, following full-year results on 14 September that showed modest Revenue growth, a return to positive cash and an outlook statement indicating trading in line with market expectations.
What the Company Does
Kromek describes itself as a global detection technology Business with Manufacturing in the UK and the US. It operates through two segments. Advanced Imaging supplies cadmium zinc telluride detector components used in medical imaging, including CT and SPECT scanners, as well as in security and industrial applications. CBRN Detection provides handheld and fixed radiation detectors for homeland security and defence customers, together with automated biological detection systems.
Latest Developments
For the year ended 30 April 2026, revenue rose 2% to £27.1m from £26.5m. Product sales were £13.8m, R&D income £3.3m and licensing revenue £10.0m, down from £16.5m a year earlier. The company delivered the second and third milestones under its enablement agreement with Siemens Healthineers, with cash received under that arrangement totalling $32.5m, including $2.5m after the year end. A final $5.0m is payable on completion of delivery, expected by 30 April 2029, and initial Supply orders from Siemens are expected to start during the current financial year.
Other contract wins highlighted in the results included a first order worth £1.7m under a UK Government radiological and nuclear detection framework, and an 18-month £0.25m contract with the Defence Science and Technology Laboratory for biological agent detection. Kromek also signed eight new distribution agreements during the year.
On the governance side, long-serving non-executive director Chris Wilkes is retiring, and chartered Accountant Jane Pearce is set to join the board after the AGM to chair the audit committee. The company also announced director share purchases on 14 and 15 September, shortly after its results.
Financial Picture
Gross Margin fell to 62.8% from 80.9%, which the company attributed mainly to the smaller share of high-margin licensing income. Adjusted EBITDA was £8.1m compared with £10.3m, while profit before tax of £2.5m was described as slightly ahead of market expectations, helped by an R&D tax credit. After a £1.7m non-cash deferred tax charge, profit after tax was £0.7m.
Cash at the year end was £4.2m, up from £1.7m, although the group reported net Debt excluding leases of £1.5m. Borrowings were mainly drawn on a three-year £6.0m revolving Credit Facility with HSBC, which the company said was being extended by £3.0m. No Dividend was referenced in the results.
Sector and index Context
Kromek sits within the technology and defence-related segment of the FTSE AIM All Share Index. Demand for its products is linked to medical imaging upgrades, including photon-counting CT, and to government spending on nuclear, radiological and biological security, areas that have received increased policy attention in Europe and the US.
Key Risks
Revenue can be lumpy, depending on the timing of milestone payments and government orders. The decline in licensing income has weighed on margins, and the company expects gross margins to settle in the mid-50s. Net debt and Working Capital requirements for growth in Advanced Imaging also merit monitoring, as does the pace at which Siemens supply orders begin.
What to Watch Next
Attention will turn to the AGM on 23 October, any trading commentary delivered there, confirmation of the extended credit facility, and the start of supply orders under the Siemens agreement. The board has said it expects further growth in the 2027 financial year.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...